Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by PICTET BANK & TRUST Ltd

PICTET BANK & TRUST Ltd decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,291 shares of the medical research company’s stock after selling 110 shares during the period. Thermo Fisher Scientific accounts for approximately 1.9% of PICTET BANK & TRUST Ltd’s portfolio, making the stock its 19th biggest position. PICTET BANK & TRUST Ltd’s holdings in Thermo Fisher Scientific were worth $1,820,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Northwest Financial Advisors purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $29,000. True Wealth Design LLC increased its holdings in shares of Thermo Fisher Scientific by 1,275.0% in the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 51 shares during the last quarter. LifeSteps Financial Inc. purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $31,000. Headlands Technologies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $32,000. Finally, Bank & Trust Co purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TMO shares. Raymond James upped their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Barclays decreased their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. Robert W. Baird increased their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Evercore ISI reduced their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $618.94.

Thermo Fisher Scientific Trading Up 0.0 %

Shares of TMO stock traded up $0.29 during mid-day trading on Friday, hitting $603.98. 1,071,948 shares of the company’s stock were exchanged, compared to its average volume of 1,547,866. The stock has a 50-day simple moving average of $570.86 and a two-hundred day simple moving average of $571.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $622.30. The stock has a market cap of $230.55 billion, a price-to-earnings ratio of 38.74, a PEG ratio of 2.77 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $5.15 earnings per share. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.71 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,084 shares of company stock worth $19,767,092. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.